Facebook Pixel Code
About Sickkids
About SickKids

Vijay Ramaswamy, MD, PhD, FRCPC

The Hospital for Sick Children
Staff Physician, Neuro-Oncology Section

Research Institute
Scientist-Track Investigator
Developmental & Stem Cell Biology

University of Toronto
Assistant Professor

Phone: 416-813-2081
Fax: 416-813-2081
Email: vijay.ramaswamy@sickkids.ca
Alternate Contact: Julia Marinescu
Alternate Phone: 416-813-7654 ext. 224679
Alternate Email: julia.marinescu@sickkids.ca

For more information, visit:

Ramaswamy Lab

Brief Biography

Dr. Vijay Ramaswamy is originally from Northern Alberta, where he completed medical school and a paediatric neurology residency at the University of Alberta (MD ’05, FRCPC ’10). Following that he completed a paediatric neuro-oncology fellowship at Memorial Sloan Kettering Cancer Center in New York, after which he came to Toronto where he completed a PhD in Cancer Genomics at the University of Toronto (PhD ’15) and a clinical neuro-oncology fellowship at The Hospital for Sick Children (SickKids). He is currently a staff neuro-oncologist in the Paediatric Brain Tumour Program at SickKids. His research interests primarily involve translational genomics of both medulloblastoma and ependymoma with a specific interest in recurrent and high-risk tumours.


2015 - present: Staff Neuro-Oncologist, Paediatric Brain Tumour Program, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON
2011 - 2015:
Clinical Research Fellow, Developmental & Stem Cell Biology research program and Paediatric Brain Tumour Program, The Hospital for Sick Children, Toronto, ON
2010-2011: Pediatric Neuro-Oncology Fellow, Memorial Sloan Kettering Cancer Center, New York
Resident, Division of Pediatric Neurology, University of Alberta Hospital, Edmonton, AB
2003: Summer Student, Department of Neurology, University of California, San Francisco, CA
1999-2002: Summer Student/Honours Student, Department of Biochemistry, University of Alberta, Edmonton, AB

Research Interests

My overall research focus is the translational genomics of medulloblastoma and ependymoma with a focus on recurrent disease. My previous and ongoing work has been primarily to apply clinical correlates to recent genomic findings, with an overarching goal of identifying new and more robust risk stratification for both entities. In addition to investigating the clinical correlations of genomics, I have an interest in leveraging genomics to identify new and novel therapies for children with recurrent brain tumors, though an integrated functional genomic approach.  This is a logical extension of my doctoral work following my Pediatric Neuro-Oncology training. My current position as a Staff Neuro-Oncologist at the Hospital for Sick Children, one of the largest pediatric brain tumour programs in the world allowing me to take the lead in translating the findings into early phase clinical trials.

Selected Publications:

  1. Liang L, Coudiere-Morrison L, Tatari N, Stromecki M, Fresnoza A, Porter CJ, Del Bigio MR, Hawkins C, Chan JA, Ryken TC, Taylor MD, Ramaswamy V*, Werbowetski-Ogilvie TE*. CD271(+) Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Res 2018; 78(16): 4745-59. PubMed PMID: 29930101. *co-senior and co-corresponding authors.
  2. Cavalli FMG, Hubner JM, Sharma T, … Aldape K, Pajtler KW, Kool M, Ramaswamy V. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018; 136(2): 227-37. PubMed PMID: 30019219
  3. Remke M, Ramaswamy V. Infant medulloblastoma - learning new lessons from old strata. Nat Rev Clin Oncol. 2018 Jul 20. doi: 10.1038/s41571-018-0071-6. [Epub ahead of print] PubMed PMID: 30030473.
  4. Cavalli FMG, Remke M, Rampasek L, …  Goldenberg A*, Ramaswamy V*, Taylor MD*. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017 Jun 12;31(6):737-754.e6. PubMed PMID: 28609654.  *co-senior and co-corresponding authors.
  5. Ramaswamy V, Taylor MD. Medulloblastoma: From Myth to Molecular. J Clin Oncol. 2017 Jul 20;35(21):2355-2363. doi: 10.1200/JCO.2017.72.7842. Epub 2017 Jun 22. Review. PubMed PMID: 28640708.
  6. Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V…  Marra MA, Taylor MD. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017 May;49(5):780-788. PubMed PMID: 28394352; PubMed Central PMCID: PMC5553617.
  7. Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 Jun;131(6):821-31. PubMed PMID: 27040285; PubMed Central PMCID: PMC4867119. *corresponding author
  8. Ramaswamy V, Remke M, Bouffet E, … Pfister SM, Korshunov A, Taylor MD. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov;14(12):1200-7. PubMed PMID: 24140199; PubMed Central PMCID: PMC3953419.
  9. Thompson EM, Hielscher T, Bouffet E, … Ramaswamy V*, Taylor MD*. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016 Apr;17(4):484-95. PubMed PMID: 26976201; PubMed Central PMCID: PMC4907853. *co-senior authors
  10. Ramaswamy V*, Remke M, Adamski J, Bartels U, Tabori U, Wang X, Huang A, Hawkins C, Mabbott D, Laperriere N, Taylor MD, Bouffet E. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. Neuro Oncol. 2016 Feb;18(2):291-7. PubMed PMID: 25605817; PubMed Central PMCID: PMC4724171. *corresponding author
  11. Pajtler KW, Mack SC, Ramaswamy V, … Pfister SM, Taylor MD. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017 Jan;133(1):5-12. PubMed PMID: 27858204; PubMed Central PMCID: PMC5209402.
  12. Ramaswamy V, Hielscher T, Mack SC, …Taylor MD. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol. 2016 Jul 20;34(21):2468-77. PubMed PMID: 27269943; PubMed Central PMCID: PMC4962737.

External Funding

Canadian Institutes for Health Research

American Brain Tumor Association

Brain Tumor Foundation of Canada

Megan’s Walk


Garron Family Cancer Center


Please see PubMed for full list of publications.